ClinicalTrials.gg
CompletedNCT06764160ECU-MG-304Updated Jan 15, 2026

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG

A Phase 3 interventional study of Eculizumab in Generalized Myasthenia Gravis (gMG) and Refractory gMG, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.

Enrollment
8th of 13
15 · median 20
Started
2025
with 3 others
Phase 3
9 of 19
2 open now
Registered
14th of 19
by date

Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2025, is one of 9 in phase 3, and was the 14th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myasthenia Gravis by AstraZeneca, or all of them as a file.
02

Study summary

This is an open-label, single-arm, multi-center study to evaluate the efficacy, safety, PK, PD, and immunogenicity of eculizumab in Chinese participants with refractory gMG. Approximately 15 participants will be enrolled in the study.

Read the detailed description

This post-approval study is an open-label, single-arm, multi-center study to evaluate the efficacy, safety, PK, PD, and immunogenicity of eculizumab in Chinese participants with refractory gMG. There will be 3 periods in this study: Screening Period (up to 4 weeks), Treatment Period (26 weeks, including an Induction Phase and a Maintenance Phase), and Safety Follow-up Period (8 weeks). The overall study duration for an individual participant is estimated to be up to 38 weeks. Approximately 15 participants will be enrolled in the study.

03

Conditions studied

  • Generalized Myasthenia Gravis (gMG)
  • Refractory gMG

Browse trials for

Keywords

  • Generalized Myasthenia Gravis (gMG)
  • Refractory gMG
  • Eculizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MG must be made by the following tests:

    1. Positive serologic test for anti-AChR Abs as confirmed at Screening, and
    2. One of the following:

      1. Abnormal neuromuscular transmission demonstrated by repetitive nerve stimulation, or
      2. History of positive anticholinesterase test, eg, neostigmine test, or
      3. Participant has demonstrated improvement in MG signs on oral cholinesterase inhibitors as assessed by the treating physician
  • MGFA Clinical Classification Class II to IV at Screening
  • MG-ADL total score must be ≥ 6 at Screening and Day 1
  • Participants who have:

    1. Failed treatment with 2 or more ISTs over one year (either in combination or as monotherapy), ie, continue to have impairment ADLs (persistent weakness, experience crisis, or unable to tolerate IST) despite ISTs or,
    2. Failed at least one IST and require chronic PE or IVIg to control symptoms, ie, participants who require PE or IVIg on a regular basis for the management of muscle weakness at least 2 cycles over last 12 months

Exclusion criteria

Exclusion Criteria:

  • Any untreated thymic , carcinoma, or thymoma
  • History of thymectomy or any other thymic surgery within 6 months prior to Screening. Participants with a history of treated thymic malignancy or carcinoma are eligible if they meet all of the following conditions:

    1. Treatment completed > 5 years prior to the Screening Visit
    2. No recurrence within the 5 years prior to the Screening Visit
    3. No radiological indication of recurrence in a computed tomography (CT) or magnetic resonance imaging (MRI) scan, including administration of intravenous (IV) contrast, performed within 6 months of first dose on Day 1
  • Weakness only affecting ocular or peri-ocular muscles (MGFA Class I)
  • MG crisis at Screening (MGFA Class V). However, such participants may be rescreened with Alexion approval once they are treated and medically stable, in the opinion of the Investigator
  • History of N meningitidis infection or unresolved meningococcal disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Eculizumab

    Eculizumab

    Drug: Eculizumab

Interventions

  • Participants will receive Eculizumab via intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. To assess the efficacy of eculizumab in the treatment of refractory gMG based on the improvement in the MG-ADL

    The mean change of Myasthenia Gravis Activities of Daily Living Profile (MG-ADL) total score from baseline at Week 26 along with 2-sided 95% CI

    Time frame: from baseline at Week 26

Secondary outcomes

  1. To assess the efficacy of eculizumab in the treatment of refractory gMG by QMG

    The mean change of quantitative myasthenia gravis (QMG) total score from baseline at Week 26 along with 2-sided 95% CI

    Time frame: from baseline at Week 26

  2. To assess the efficacy of eculizumab in the treatment of refractory gMG by MGC

    The mean change of myasthenia gravis composite (MGC) total score from baseline at Week 26 along with 2-sided 95% CI

    Time frame: from baseline at Week 26

  3. To assess the efficacy of eculizumab in the treatment of refractory gMG by MG-QoL 15r

    The mean change of revised Myasthenia Gravis Quality of Life 15-Item Scale (MG-QoL 15r scale) from baseline at Week 26 along with 2-sided 95% CI

    Time frame: from baseline at Week 26

  4. To assess the efficacy of eculizumab in the treatment of refractory gMG by MG-ADL responder status

    The proportion of participants who achieve the Myasthenia Gravis Activities of Daily Living Profile (MG-ADL) response at Week 26, along with the 2-sided 95% CI

    Time frame: from baseline at Week 26

  5. To assess the efficacy of eculizumab in the treatment of refractory gMG by QMG responder analysis

    The proportion of participants who achieve the quantitative myasthenia gravis (QMG) response at Week 26, along with the 2-sided 95% CI

    Time frame: from baseline at Week 26

  6. To assess the safety and tolerability of eculizumab in the treatment of refractory gMG

    Incidence of AEs, SAEs, and AEs leading to study intervention discontinuation (onset after first infusion)

    Time frame: from baseline at Week 26

  7. To characterize the PK of eculizumab in participants with refractory gMG

    Mean serum eculizumab concentrations at all scheduled visits

    Time frame: from baseline at Week 26

  8. To characterize the PD of eculizumab in participants with refractory gMG

    Mean changes in serum free complement component 5 (C5) concentrations at all scheduled visits

    Time frame: from baseline at Week 26

  9. To characterize the immunogenicity of eculizumab in participants with refractory gMG

    Proportion of treatment-emergent anti-drug antibody (ADA) positive participants

    Time frame: from baseline at Week 26

07

Study locations

6 sites
  • Research Site
    Changchun, 130021, China
  • Research Site
    Fuzhou, 350001, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510620, China
  • Research Site
    Qingdao, 266035, China
  • Research Site
    Shanghai, 200040, China
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Dec 2025, 11 months.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 11 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Jan 8, 2025
StartActual
Jan 6, 2025
Primary completionActual
Dec 29, 2025
CompletionActual
Dec 29, 2025
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06764160
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Jan 6, 2025
Primary completion
Dec 29, 2025
Completion
Dec 29, 2025
Last update
Jan 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion